Drug Profile
Research programme: cancer therapeutics - ACTSBIO
Latest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator ACTSBIO
- Class Antineoplastics
- Mechanism of Action Tumour suppressor gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Sep 2023 Discontinued - Preclinical for Cancer in South Korea (unspecified route), prior to September 2023
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in South Korea
- 09 Aug 2016 Preclinical trials in Cancer in South Korea (unspecified route)